ATOSSA THERAPEUTICS INC
ATOSNASDAQTrading Snapshot
- Day Range
- $2.36 – $2.42
- 52-Week Range
- $1.70 – $14.85
- Volume (shares)
- 29,410
- Avg Volume (shares)
- —
- Shares Outstanding
- 10.0M
- Next Earnings
- 2026-11-10
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- 147.8x
- EPS (TTM)
- $-4.34
- Dividend Yield
- —
- Dilution (1yr)
- +2.0%
ATOSSA THERAPEUTICS INC
ATOS
StockOtter · stockotter.spaceAbout ATOSSA THERAPEUTICS INC
Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative medicines. Their primary focus lies in addressing unmet medical needs in women's oncology, especially breast cancer, along with other conditions, within the United States. The company's flagship therapeutic candidate is oral (Z)-endoxifen. This compound, an active metabolite derived from tamoxifen, is currently undergoing Phase II clinical trials for both the treatment and prevention of breast cancer. Beyond this, Atossa is also advancing immunotherapy and chimeric antigen receptor (CAR) therapy programs. Established in 2008, the company adopted its current name, Atossa Therapeutics, Inc., in January 2020, having previously operated as Atossa Genetics Inc. It is headquartered in Seattle, Washington.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today
One CVR will attach to each outstanding share of Atossa common stock as of the close of business on October 19, 2026, and shares and CVRs will transfer together while stapled Shares issued after October 19, 2026 will als
Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value
Board declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2026 record date or issued thereafter CVRs entitle holders to 25% of net proceeds from monetization of Atossa's first qua
Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher
Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter CVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review vouc
Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging
Panel at Harvard University will explore translating evidence in diseases of aging into new therapeutics and regulatory pathways SEATTLE, Sept. 24, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa"
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
SEATTLE, Aug. 7, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clin